Table 3.
Differences in concomitant treatments between groups
| Intensive (%) | Standard (%) | P value | |
|---|---|---|---|
| ADVANCE [17] |
|
|
|
| -Antihypertensive drugs |
88.9 |
88.4 |
0.44 |
| -Statins |
45.6 |
47.7 |
0.09 |
| -Other cholesterol-lowering drugs |
7 |
7 |
0.90 |
| -Aspirin |
57 |
54.9 |
0.02 |
| -Other anti-aggregating drugs |
7.1 |
6.2 |
0.07 |
| ACCORD [18] |
|
|
|
| -Anti-hypertensive drugs |
91 |
92 |
0.06 |
| -ACEIs |
69.7 |
71.9 |
0.02 |
| -Beta blockers |
47.5 |
48.6 |
0.27 |
| -Statins |
88 |
87.6 |
0.54 |
| -Aspirin |
75.5 |
75.5 |
0.98 |
| Kumamoto [16] |
11 |
11 |
1 |
| -Statins |
3.6 |
5.4 |
0.66 |
| -Fibrates |
0 |
0 |
- |
| -Aspirin |
1.8 |
3.6 |
0.60 |
| - Antiplatelet therapy |
12.7 |
18.1 |
0.45 |
| -ACEI |
0 |
|
- |
| -ARB |
ACEI angiotensin-converting enzyme inhibitors.
ARB angiotensin-receptor blockers.